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ABSTRACT 
Mature enzymes encoded within the human immunodeficiency virus type 1 (HIV-1) genome 
[protease (PR), reverse transcriptase (RT) and integrase (IN)] derive from proteolytic processing 
of a large polyprotein (Gag-Pol).  Gag-Pol processing is catalyzed by the viral PR, which is active 
as a homodimer.  The HIV-1 RT functions as a heterodimer (p66/p51) composed of subunits of 
560 and 440 amino acids, respectively.  Both subunits have identical amino acid sequence, but 
p51 lacks 120 residues which are removed by the HIV-1 PR during viral maturation.  While p66 
is the catalytic subunit, p51 has a primarily structural role.  Amino acid substitutions affecting the 
stability of p66/p51 (i.e. F130W) have a deleterious effect on viral fitness.  Previously we showed 
that the effects of F130W are mediated by p51 and can be compensated by mutation T58S.  While 
studying the dynamics of emergence of the compensatory mutation, we observed that mutations in 
viral PR-coding region were selected in HIV clones containing the RT substitution F130W, before 
the imposition of T58S/F130W mutations.  The identified PR mutations (G94S and T96S) 
improved the replication capacity of the F130W mutant virus. By using a trans-complementation 
assay, we demonstrate that the loss of p66/p51 heterodimer stability caused by Trp-130 can be 
attributed to an increased susceptibility of RT to viral PR degradation.  Recombinant HIV-1 PRs 
bearing mutations G94S or T96S showed decreased dimer stability and reduced catalytic 
efficiency.  These results were consistent with crystallographic data showing the location of both 
residues in the PR dimerization interface.   
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Introduction 
The genome of all replication-competent retroviruses consists of at least three genes 
required for viral infection and replication, arranged in the order 5´-gag-pol-env-3 .´  In the human 
immunodeficiency virus type 1 (HIV-1), the expression of those retroviral genes leads to the 
formation of three polyproteins Gag (Pr55Gag), Gag-Pol (Pr160Gag-Pol), and Env (Pr160Env).  The 
structural proteins of the virus [matrix protein (MA), capsid protein (CA), p2 and nucleocapsid 
protein (NC)] arise from the proteolytic processing of Gag by the retroviral protease (PR).1  A 
ribosomal frameshift between the gag and pol genes leads to the synthesis of the Pr160Gag-Pol 
precursor.  The three retroviral enzymes: PR, reverse transcriptase (RT) and integrase (IN) are 
encoded in the Pol open reading frame, and arise from the proteolytic processing of Gag-Pol by 
the viral PR.   
The HIV-1 PR is a homodimeric enzyme, composed of two identical subunits of 99 amino 
acids.  Each subunit contains the conserved sequence Asp-Thr-Gly, which provides the aspartyl 
group necessary for catalysis.  Crystal structures and biochemical studies have shown that major 
interactions that stabilize the mature dimer appear in a four-stranded antiparallel β-sheet, where 
the N-terminal residues of each of the PR monomers form the outer strands of the β-sheet, and the 
C-terminal residues of each monomer form the two inner strands2 (review 3).  PR dimerization and 
autocatalytic release from Gag-Pol are critical steps in the viral life cycle.4-6 
The HIV-1 RT is a heterodimer composed of subunits of 66 kDa (p66) and 51 kDa 
(p51).7,8  The p66 subunit has 560 amino acids and contains DNA polymerase and endonuclease 
(RNase H) domains. The p51 subunit has the same amino acid sequence as p66, but lacks the 120 
residues of the C-terminal region forming the RNase H domain.  Crystallographic studies have 
shown that the polymerase domains of both p66 and p51 contain four subdomains: fingers, palm, 
 4 
thumb and connection.9  In the p51 subunit, these subdomains adopt a “close” conformation, with 
its catalytic residues occupying an internal position in the molecule.9-11  The HIV-1 RT 
heterodimer arises from the viral PR-mediated cleavage of the Pr160Gag-Pol precursor, although the 
precise pathway for the formation of RT heterodimers in HIV-infected cells is not fully 
understood.  The p51 subunit plays a largely structural role in the heterodimer.12-14  Structural 
studies have allowed the identification of major contacts between p66 and p51.  In p51, residues 
52-55 and 135-140 in the fingers subdomain, 255-265 and 286-290 in the thumb subdomain, and 
393-402 and 420-423 in the connection subdomain generate the largely hydrophobic surface that 
interacts with p66.15  Several non-conservative mutations in p51 that affect residues of the β7-β8 
loop (positions 134-139)16-19 or the so-called “Trp motif” (residues 398, 401, 402, 406, 410 and 
414)20,21 are known to impair RT dimerization, while producing a loss of viral infectivity. 
Previously, we showed that the substitution of Trp for Phe-130 in the HIV-1 RT rendered 
a virus with diminished replication capacity.22  The deleterious effects of F130W were attributed 
to the loss of stability of p51, based on the characterization of chimeric recombinant RTs with 
mutated or wild-type subunits.  A compensatory mutation in the RT-coding region (T58S) was 
selected upon passaging the virus in cell culture.22  A detailed study of the dynamics of imposition 
of double-mutant T58S/F130W has now revealed the early presence of viral subpopulations 
containing mutations in the dimerization region of the viral PR.  Here, we provide further 
evidence on the deleterious effects of F130W on the stability of p51 using a trans-
complementation assay.23  The presence of F130W renders p51 susceptible to the viral PR.  The 
increased viral replication capacity conferred by the compensatory PR mutations G94S (and less 
frequently, T96S) appears to be a consequence of their destabilizing effect on the PR dimer, 
which renders an enzyme with reduced proteolytic activity.  
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Results 
Analysis of compensatory mutations emerging with the replication-deficient mutant F130W    
Our previous studies showed that cultures transfected with a mutant proviral DNA of HIV-
1 subtype B strain 89ES061, carrying a F130W substitution in the RT-coding region rendered 
virus with impaired replication.22  However, successive passages of the mutant virus in cell 
culture led to selection of T58S in the viral RT.  This compensatory mutation restored viral 
replication capacity, in the absence of additional mutations in the gag and pol genes of mutant 
HIV-1 containing F130W (Figure 1 (a),(b)).22  Viral protein expression analysis revealed that all 
three viruses (i.e. wild-type HIV-1 and mutants F130W and T58S/F130W) produced significant 
amounts of p24 and IN, although mutant F130W showed delayed maturation.  As shown in Figure 
1 (c), the ratio of p24 to its Gag precursor is similar for the wild-type HIV-1 and the double 
mutant T58S/F130W, but significantly lower for the single-mutant F130W.  Interestingly, 
Western blot analysis with monoclonal antibodies against the RNase H domain of the RT (p66 
subunit) (Figure 1 (e)) or the RT heterodimer (p66/p51) (Figure 1 (f)) revealed undetectable levels 
of the viral polymerase in the cultures infected with the F130W mutant.  These results were 
consistent with the lower RT activity detected in those culture supernatants (Figure 1 (a)).  In 
addition, the similar levels of IN observed with the three variants analyzed suggested that the 
lower RT levels were not related to a defect in Gag-Pol expression. 
In an attempt to study the population dynamics leading to the imposition of the double 
mutant T58S/F130W, we carried out a series of transfection experiments with mutant HIV-
189ES061 provirus containing the F130W mutation alone.  The viral stocks obtained after infecting 
MT-4 cells with supernatants from transfection experiments were analyzed by DNA sequencing.  
The nucleotide sequence of the viral stock of mutant F130W used in the experiments shown in 
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Figure 1 was rather homogeneous, since it had only the relevant mutation, with potential 
heterogeneities representing less than 10 % of the total virus population.  However, other stocks 
of the F130W mutant contained nucleotide sequence heterogeneities in the PR-coding region 
(Figure 2 (a)).  In one of them, the compensatory mutation in the RT-coding region (T58S) was 
present in about 20 % of the viral population.  Clonal analysis of that viral stock showed that 40 
% of the clones contained the F130W mutation alone.  A number of clones had F130W in 
combination with the PR mutation G94S and others contained both RT mutations (T58S and 
F130W) (Figure 2 (b)).  After two passages of this virus in MT-4 cells, the double-mutant 
T58S/F130W became predominant.   
Additional transfection experiments with mutant HIV-1 having the RT mutation F130W 
revealed the presence of HIV variants carrying mutations in the C-terminal region of the PR.  In 
four out of five viral stocks, G94S-containing variants represented 10 to 60 % of the total 
population found in the corresponding viral stock.  In one case, the transfection supernatant 
contained virus which had acquired the PR mutation T96S (Figure 2 (a)).    
Although the PR mutation G94S was usually found as a relatively minor component of the 
quasispecies recovered from viral stocks, infection of MT-4 cells with stock no. 2 (which 
contained the lowest proportion of G94S-containing virus) showed the rapid imposition of the 
double mutant [PR (G94S) + RT (F130W)] over the mutant containing the F130W mutation alone 
(Figure 2 (c)). Taken together, these data suggest that G94S has a positive effect on viral fitness, 
although the clonal analysis of the viral populations passaged in MT-4 cells showed that the 
double-mutant T58S/F130W was even fitter and became predominant after two passages in cell 
culture (Figure 2 (b)).   
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The compensatory effect of G94S was confirmed with infectious HIV-189ES061 clones, after 
cotransfection of 293T cell monolayers.  In those cells, the emergence of compensatory mutations 
is minimized because cell culture supernatants are used directly in replication kinetics and 
infectivity assays, without further viral replication in MT-4 cells, as required for transfections of 
COS-1 cells.  The amount of p24 antigen in 293T cell supernatants was roughly similar for wild-
type and mutant HIV-189ES061 clones, although we detected large differences in viral infectivity 
(Figure 3 (a)).  The wild-type was about 42 times more infectious than the double mutant [PR 
(G94S) + RT (F130W)], and >2900 times more infectious than the virus collected from cell 
supernatants of transfections carried out with mutant F130W.  Although both mutant viruses 
showed diminished replication capacity in comparison with the wild-type HIV-1, the detection of 
RT activity at days 17 - 21 in MT-4 cell culture supernatants infected with the double mutant [PR 
(G94S) + RT (F130W)] (Figure 3 (b)) helps to further confirm the compensatory effect of the 
G94S mutation. 
By themselves, the PR mutations G94S and T96S had a relatively minor effect on viral 
infectivity in comparison with the wild-type HIV-189ES061 clones, with titers in the range of 0.8 – 
1.4 and 0.6 – 1.4 TCID50 per pg of p24, for G94S and T96S, respectively.  However, competition 
assays carried out in MT-2 cells at a multiplicity of 0.001 showed the higher fitness of the wild-
type clones over the mutant HIV carrying mutation G94S (data not shown). 
 
Effects of F130W on the stability of p51    
The constructs M7 and vpr-IN, together with wild-type or mutated vpr-p51/p66 (Table 1) 
were used to cotransfect 293T cell monolayers.  M7 is a provirus lacking the RT- and IN-coding 
regions.23  In this trans-complementation assay, Vpr-51 incorporates p66 through interaction and 
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stable association of the two RT subunits (Vpr-51 and p66) within the cellular cytoplasm.  
Specific interaction between Vpr and the Gag precursor polyprotein leads to the incorporation of 
the Vpr-p51/p66 complex into the progeny virus, and subsequent cleavage by the viral PR 
generates wild-type RT heterodimer.  
Immunoblot analysis of the transfection-derived virions showed that the trans-
p66/p51F130W mutant had significantly reduced amounts of both p66 and p51 RT subunits 
compared to the wild-type trans-p66/p51 (Figure 4 (a)).  Interestingly, the presence of the T58S 
mutation in combination with F130W in the p51 subunit restored the levels of virion-associated 
RT subunits (lane 4). As expected, M7 virions trans-complemented with vpr-∆p51/p66 did not 
show RT subunit packaging (lane 2).  We confirmed that approximately the same amount of virus 
was analyzed in each sample by probing the blot with a monoclonal antibody recognizing HIV-1 
CA (Figure 4 (a), lower panel).  Western blot analysis of the corresponding cell lysates using a 
monoclonal antibody specific for the 66-kDa subunit of HIV-1 RT (Figure 4 (b)), or antisera 
against Vpr (not shown) revealed that the expression of both proteins was not impaired for the 
mutant clones.  The amount of cellular protein analyzed in each sample was similar, as 
demonstrated with a monoclonal antibody specific for human α-tubulin.   
The results shown in Figure 4 suggest that the mutant p51 is degraded during viral 
packaging or maturation.  We studied the effects of p51F130W after cotransfecting the 293T cell 
monolayers with an HIV construct lacking an active PR (designated as PM-3),4 in order to 
discriminate between viral or cellular PR-mediated processing.  The PM-3 virus contains Asn 
instead of Asp-25 in the catalytic site of the viral PR.  The immunoblot analysis of virions 
generated by cotransfection with PM-3, vpr-p51/p66 and vpr-IN showed significant amounts of 
Vpr-p51 and p66 in the released viral particles (Figure 5, lane 1). As expected, the p66 subunit 
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was not incorporated into virions obtained with PM-3 and vpr-∆p51/p66 (lane 2).  Interestingly, 
the PM-3 virions obtained with vpr-p51(F130W)/p66 contained wild-type levels of Vpr-p51, 
suggesting that the lower stability of p51 due to the presence of F130W could be a consequence of 
its higher susceptibility to viral PR degradation (lane 3).  Also, two bands related to p66 were 
observed in the vpr-p51(F130W)/p66 virions. Similar p66-derived double bands have been 
described for RT mutations that are in the vicinity of the dimer interface and likely result from 
cleavage by cellular proteases.19,21  The simultaneous presence of both mutations T58S and 
F130W in the p51 subunit also prevented processing of the p66 subunit by non-viral PRs (lane 4), 
further emphasizing the importance of the T58S mutation in increasing p66/p51F130W heterodimer 
stability and decreasing sensitivity to PR degradation. 
 
Effects of G94S and T96S on the proteolytic activity and dimerization properties of the viral 
PR   
Since G94S and T96S emerged as mutations that compensate for the replication defect 
caused by F130W in the viral RT, we analyzed the effects of substituting Ser for Gly-94 or Thr-96 
in the viral PR.  Wild-type and mutant PRs were expressed in E. coli and purified from inclusion 
bodies.  The specific activities of the three enzymes were compared in an HPLC assay, using a 
synthetic nonapeptide (Val-Ser-Gln-Asn-Tyr*Pro-Ile-Val-Gln, asterisk indicates the cleavage site) 
as a substrate of the proteolytic reaction.  The peptide mimics the naturally occurring cleavage site 
between the HIV-1 proteins MA and CA.  As shown in Table 2, wild-type and mutant PRs are 
able to cleave the oligopeptide substrate.  However, in comparison with the wild-type enzyme, 
both mutants G94S and T96S showed decreased catalytic efficiency.  The largest effects were 
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observed with G94S.  Its catalytic constant (kcat) was about 4.4 times reduced in comparison with 
the wild-type PR, while its Km was increased by about 5-fold.   
Gly-94 and Thr-96 map within the dimerization region of the PR homodimer, and away 
from the substrate binding site.2  Since dimerization properties and the proteolytic activity of the 
viral PR are related to each other, we measured the effects of the mutations in PR stability by 
urea-denaturation.  As shown in Figure 6 (a), both mutants G94S and T96S showed increased 
susceptibility to the denaturing agent in comparison with the wild-type PR.  In agreement with the 
lower catalytic activity and susceptibility to urea denaturation, the dissociation constants (Kd) for 
G94S and T96S were estimated at 26.3 and 4.94 nM, respectively (Figure 6 (b)).  In contrast, we 
did not observe any significant decrease in the specific proteolytic activity at the lowest measured 
concentration of active wild-type PR (< 0.37 nM).  These data reveal a correlation between the 
lower specific activity of both PR mutants, and particularly of G94S, and their reduced dimer 
stability.   
 
Discussion 
Both HIV-1 PR and RT are synthesized as part of large precursor polyproteins which are 
used in the assembly of immature virions.  The PR-mediated cleavage of these precursors leads to 
the formation of infectious virus.  The active form of HIV-1 RT is a p66/p51 heterodimer, which 
can be obtained in vitro by treatment of purified recombinant p66/p66 RT homodimers with HIV-
1 PR.24  In addition, coexpression of p66 RT and HIV-1 PR provides good yields of stable 
p66/p51 RT heterodimers,25 an observation that has been also interpreted as evidence suggesting 
that RT heterodimer formation proceeds through a p66/p66 RT homodimer intermediate.  Recent 
data based on a model 90-kDa Pol polyprotein containing the transframe protein, PR, RT and the 
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N-terminus of IN appears to support this proposal.26 However, the precise pathway for the 
formation of RT heterodimers in HIV-infected cells is still poorly understood.  Biochemical 
studies have shown that both p66/p66 homodimers and p66/p51 heterodimers retain significant 
DNA polymerase activity in vitro,12,13,27 although heterodimers are more stable than p66/p66 
homodimers.28  Available evidence suggest that the stabilizing role of p51 is critical to maintain 
RT function during the viral life cycle. 
Our previous studies showed that substituting Trp for Phe-130 had a deleterious effect on 
viral replication.  In addition, we showed that the F130W substitution compromised the stability 
of p51, probably by making the polypeptide more susceptible to proteases.22  However, these 
studies were carried out with recombinant HIV-1 RT expressed in E. coli, and extrapolating these 
results to conditions found in HIV-infected cultures may not be correct.  In the context of a 
normal proviral genome, the F130W substitution had a significant impact on RT stability.  
Western blot analysis showed that the expression levels of p24 and IN were normal, in contrast 
with the RT which remained almost undetectable (Figure 1). 
The results of the trans-complementation system, developed to study the impact of 
mutations in specific subunits of HIV-1 RT in the context of a viral infection,29 were in agreement 
with the data obtained with recombinant chimeric RTs.  Interestingly, the presence of F130W in 
p51 produced a large reduction in the amount of packaged p66/p51 in mature virions, although the 
proportion of p66 to p51 was relatively close to 1:1.  These results were rather different from 
those obtained with mutants impairing RT dimerization, whose levels of packed Vpr-p51 (and 
processed p51) were roughly similar to those obtained with the wild-type constructs.21,23  The 
reduction in RT subunit content was consistent with a reduced viral infectivity (data not shown).  
The absence of both RT subunits in virions could not be attributed to reduced expression of either 
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p66 or p51.  In contrast to the results described above, the analysis of virions recovered after 
cotransfection with an HIV construct containing a catalytic mutant PR showed similar levels of 
packed Vpr-p51, thereby suggesting that the viral PR could be responsible for the loss in RT 
heterodimer stability produced by F130W when present in p51.  The presence of the T58S 
mutation along with F130W in the 51-kDa subunit produced a significant increase in the levels of 
virion-associated RT subunits, in comparison with mutant F130W, while protecting the RT 
subunits from cellular PR-mediated degradation within the viral particles.    
Although the compensatory mutation T58S in the viral RT restores the replication capacity 
of virus harboring F130W, a detailed study of the viral populations present in transfection 
supernatants and early passages of the F130W mutant revealed that the first second-site mutations 
that appear in the viral population occur within the PR-coding region.  G94S appeared in 4 out of 
5 viral stocks, while T96S emerged as a compensatory mutation in the fifth experiment.  The 
appearance of G94S in the viral PR improved the viral replication capacity of mutant virus 
carrying the substitution F130W, but the viral fitness of the double-mutant was relatively low in 
comparison with the wild-type enzyme.  The biochemical characterization of the mutant PRs 
carrying mutations G94S or T96S showed that both mutations produced a significant reduction in 
proteolytic activity, which was more pronounced in the case of G94S.  These data were consistent 
with published rough estimates of proteolytic activity obtained with PR mutants such as G94A, 
T96A, or T96S.30,31  Further evidence on the effects of G94S in viral maturation was obtained 
from immunoblot analysis of vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 virions.  
Virus carrying the PR mutation G94S and the RT substitution F130W showed higher amounts of 
unprocessed Gag than those virions containing only F130W (A. Mulky, unpublished 
observations). 
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The effects on the proteolytic activity can be attributed to impaired dimerization, as shown 
by the results of urea denaturation assays and Kd determinations. In agreement with this proposal, 
the analysis of published crystal structures shows that residues 94 and 96 are part of the four-
stranded β-sheet responsible for a large portion of the PR dimerization interactions (Figure 7).  
Hydrogen bonds between the CO and NH groups of Thr-96 of one of the PR subunits and the NH 
and CO groups of Asn-98 in the other subunit contribute to the stabilization of the β-sheet.  In 
addition, hydrogen bonds involving hydroxyl and amido groups in the side chains of Thr-96 and 
Asn-98, respectively contribute to stabilize each PR subunit. The substitution of Ser for Thr-96 
could affect the hydrogen bond network.  Gly-94 is not involved in hydrogen bonding interactions 
within the β-sheet.  However, it is located next to a loop and at the N-terminus of a β-strand 
comprising residues 94-99.  The substitution of Ser for Gly-94 is expected to destabilize the β-
sheet that forms the dimerization interface of the PR. 
Although the identified PR mutations may cause a delay in viral maturation, their lower 
proteolytic activity is expected to increase the stability of the mutated p51.  It has been reported 
that mutations that impair RT heterodimerization such as N136A, W401A or W401L lead to the 
formation of noninfectious viruses with reduced levels of virion-associated and intracellular RT 
activity in comparison with the wild-type variants.19,21,32  Using the trans-complementation assay, 
Mulky et al. have shown that substituting Ala for Asn-136 in the β7-β8 loop of p51 destabilizes 
the heterodimeric RT, while rendering the 51-kDa subunit susceptible to degradation by the viral 
PR.19  In addition, Wapling et al. showed that the HIV-1 PR contributed to the degradation of 
virion-associated subunits when mutations at position 401 were present.32  Authors argued that the 
loss of a proper RT dimer interface led to inefficient Gag-Pol dimerization, a step that is required 
for autocatalytic activation of the viral PR.32  Although NC binding to viral RNA as well as other 
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dimerization domains in Gag and Pol also have an important role in viral assembly,33 minimizing 
at least in part the effects of RT mutations, we cannot rule out the possibility of F130W having a 
deleterious effect on Gag-Pol polyprotein conformation.  Crystal structures of HIV-1 RT show 
that the side-chain of Phe-130 in the p51 subunit contacts residues such as Asn-57 and Arg-143, 
which are involved in interactions stabilizing the RT heterodimer.9-11,22  These interactions might 
be required for the proper temporal cleavage of Gag-Pol, and their loss could be compensated in 
part by mutations in the PR dimer interface. 
Recently published data suggest that the proteolytic cleavage rendering the p66/p51 
heterodimer plays an important role in the stabilization of the viral RT during viral maturation.  
Extensive mutagenesis studies have shown that amino acid substitutions affecting residues in the 
vicinity of the p51/RNase H cleavage site (RT positions 440-441) often lead to the loss of viral 
infectivity due to diminished virion RT levels.34  Although those experiments show no correlation 
between the type of mutation, its location and the obtained RT levels, it was clear that certain 
mutations rendered RTs highly susceptible to PR degradation.  Taking together, those data 
suggest that proteolytic removal of one of the RNase H domains in the p66/p66 homodimers may 
be essential for providing a stable conformation of the viral RT, resistant to further proteolytic 
degradation within the virion.  Further evidence suggesting that mutations affecting RT 
conformation have an impact on viral maturation was obtained from experiments carried out with 
virus carrying RT mutations L234D and W239A. Those residues are not involved in dimer 
interactions, but produce a loss of infectivity, which has been attributed to the premature cleavage 
of the Gag-Pol precursor.35  Although Phe-130 does not participate in intersubunit interactions, 
this residue could have an influence on the conformation of the β7-β8 loop of p51.22  Several 
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amino acid substitutions within the β7-β8 loop of p51 are known to impair heterodimer formation, 
while decreasing the DNA polymerase activity of the viral RT in enzymatic assays.16-18   
Molecular mechanisms leading to fitness recovery play an important role in antiretroviral 
therapy. Evolution of drug resistance is characterized by severe fitness losses, which can be 
partially overcome by compensatory mutations or other adaptive changes that restore viral 
replication capacity.  This process involves structurally relevant amino acid substitutions in target 
enzymes (i.e. PR, RT or IN) (review36), changes in substrates of those enzymes (i.e. substitutions 
in the cleavage sites of Gag and Gag-Pol polyproteins),37-39 or modifications elsewhere in the 
genome that could affect viral protein expression (i.e. changes in the frameshift signal40) or 
packaging of Pol proteins.41  In the case of HIV-1 RT, all second-site reversions described so far 
involve mutations within the RT-coding region.42,43  The identification of PR mutations that affect 
viral maturation, while compensating for viral replication defects caused by mutations affecting 
the stability of the viral RT emerges as a novel strategy to increase viral fitness. It is also 
anticipated that compensatory mutations in the PR dimer interface could play a role in the 
acquisition of resistance to inhibitors of RT dimerization, whose development still remains at a 
pre-clinical stage.   
 
Materials and Methods 
Cell lines, antibodies and molecular clones   
COS-1, MT-4 and MT-2 cells were maintained in RPMI 1640 medium supplemented with 
10% fetal bovine serum and 2 mM glutamine. The 293T cell cultures were grown in Dulbecco’s 
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modified Eagle’s medium (DMEM) supplemented with 10 % fetal bovine serum, penicillin (100 
units/ml) and streptomycin (0.1 mg/ml).   
Antibodies used included polyclonal anti-Vpr serum44 and monoclonal antibodies to 
human α-tubulin and β-actin (Sigma), HIV-1 CA (183-H12-C5, contributed by B. Chesebro and 
H. Chen), HIV-1 IN (8G4, contributed by D. E. Helland), HIV-1 RT (p66/p51 heterodimer) (8C4 
and 5B2B2, contributed by D. E. Helland and A. M. Szilvay), and the RNase H domain (p66 
subunit) of HIV-1 RT (7E5, contributed by D. E. Helland). Antibodies against HIV proteins were 
obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH.   
Plasmids p61F A and p61F B containing the 5’ and 3’ ends of the proviral DNA of the 
HIV-1 subtype B isolate 89ES061 and a mutant derivative of p61F A containing the F130W 
mutation in the RT-coding region were previously described.22,45 Cotransfection with plasmids 
p61F A and p61F B renders infectious virus after in vivo ligation.45  Mutant HIV-189ES061 clones 
were obtained by site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene) by following the manufacturer’s instructions, using the plasmid p61F A as template.  
The mutagenic primers 5´-CTG TTG ACT CAG ATT AGT TGC ACT TTA AAT TTT CCC-3  ´
and 5´-GGG AAA TTT AAA GTG CAA CTA ATC TGA GTC AAC AG-3  ´were used to obtain 
virus harboring the PR mutation G94S.  Primers 5´-CTG TTG ACT CAG ATT GGT TGC TCT 
TTA AAT TTT CCC-3  ´and 5´-GGG AAA TTT AAA GAG CAA CCA ATC TGA GTC AAC 
AG-3  ´were used to introduce T96S in the viral PR. All mutations were confirmed by DNA 
sequencing. 
The HIV-1 pSG3 (SG3) proviral clone (GenBank accession number L02317)46 was used 
to construct all proviral and recombinant RT and IN expression plasmids, used in the trans-
 17 
complementation assay (construct names are listed in Table 1).21  The PM-3 proviral plasmid 
contains a mutation in the PR-coding region that renders PR inactive due to the presence of Asn 
instead of Asp-25 in its catalytic site.4  The RT-IN-minus pSG3M7 (M7) proviral construct 
described previously23 was used for trans-complementation analysis with all the pLR2P-based RT 
and IN expression plasmids.  The RT subunits were expressed in trans using the previously 
described pLR2P-vpr-45Prop51-IRES-p66 (vpr-p51/p66) plasmid.29 Derivatives of vpr-p51/p66 
having mutations in p51 were obtained by cloning the RT-coding region from the previously 
described pRT6 plasmid containing mutations F130W or T58S/F130W,22 into vpr-p51/p66. All 
clones were confirmed by nucleotide sequencing. 
 
Transfections and analysis of virus infectivity   
DNA transfections were performed on monolayer cultures of COS-1 cells, by 
electroporation as previously described22,45 or 293T cells using the calcium phosphate 
precipitation method. Usually, 293T cells were seeded at 4 x 106 in 10-cm-diameter tissue culture 
plates one day prior to transfection.  Monolayers were then transfected with 10 µg of proviral 
HIV-189ES061 DNA. Culture supernatants from the 293T cells were collected 72 h post-
transfection, clarified by low-speed centrifugation (1,000 x g, 10 min), and filtered through 0.45 
µm pore-size sterile filters.  The clarified supernatants were assayed for HIV-1 p24 concentration 
by ELISA.  In transfections carried out with COS-1 cell monolayers, MT-4 cells were added 48 h 
after transfection to increase the relatively low viral titers. 
To obtain a virus stock, supernatants from transfection experiments on COS–1 cells, 
collected at days when maximum levels of RT activity were detected were used to infect 5 x 106 
fresh MT-4 cells to increase viral production. Viral stocks were titrated in MT-2 cells and titers 
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were calculated by the Spearman-Karber method, and expressed as TCID50.47  Infections were 
then carried out at a multiplicity of infection of 10-3 to 10-4 TCID50 per cell.  Viral replication was 
monitored by measuring RT activity and p24 concentration in culture supernatants as previously 
described,22 and estimating cell viability using the trypan blue staining method.  Detection of viral 
proteins by Western blot was carried out as described.22 Supernatants from 293T cell transfections 
were used without further co-cultivation in infectivity assays. 
 
RNA isolation, amplification, and nucleotide sequence analysis   
Culture supernatants were passed through 0.45-µl pore size filters and treated with DNase 
A for 30 min to eliminate input DNA.  Total RNA was isolated from 20 µl-aliquots of culture 
supernatants obtained from transfections (or infections).48  RNA amplification was done with the 
Qiagen OneStep RT-PCR kit (Qiagen) using primers PRF1 (5´-CAG CCC CAC CAG AAG AGA 
GC-3´) and 59RD (5´-ATG ATT CCT AAT GCA TAT TGT GAG T-3´), which correspond to 
positions 2156-2175 and 4042-4066, respectively, according to the numbering of the HIV-1 
HXB2CG strain (GenBank accession no. K03455).  For quasispecies analysis, the polymerase 
chain reaction products were cloned using the TA cloning kit (Invitrogen, Carlsbad, California), 
and sequenced with the Big Dye Terminator Cycle Sequencing kit (Applied Biosystems), using an 
ABI-PRISM 377 DNA sequencer.  
 
Immunoblot analysis   
For trans-complementation studies, DNA transfections of 293T cells were performed in 
six-well plates.  Monolayers were transfected with 6 µg of proviral DNA (M7 or PM-3), 3 µg of 
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the vpr-p51/p66 constructs and 1 µg of the vpr-IN construct.  Culture supernatants from the 293T 
cells were collected 60 h posttransfection, clarified by low-speed centrifugation (1000 x g, 10 
min), and filtered through 0.45 µm pore-size sterile filters.  Transfection-derived virions were 
concentrated by ultracentrifugation through 20% (w/v) sucrose cushion (125,000 x g, 2 h, 4 ºC) 
using a SW41 rotor (Beckman Inc.). Pellets were solubilized in Laemmli loading buffer (62.5 mM 
Tris, pH 6.8, 0.2 % SDS, 5 % β-mercaptoethanol, 10 % glycerol), boiled, and proteins were 
separated on 12 % polyacrylamide gels containing SDS.  Following electrophoresis, proteins were 
transferred to nitrocellulose (0.2 µm pore size) by electroblotting and incubated for 1 h at room 
temperature in blocking buffer (5 % non-fat dry milk in phosphate-buffered saline).  The blocked 
blots were exposed to antibody for 1 h in blocking buffer with constant mixing. After extensive 
washing, bound antibodies were detected by chemiluminiscence using horseradish peroxidase-
conjugated species-specific secondary antibodies (Southern Biotechnology Associates, Inc.) as 
described by the manufacturer (GE Healthcare). 
 
Mutagenesis, expression and purification of recombinant HIV-1 PRs   
The E. coli strain BL12(DE3)pLysS harboring the plasmid pET-HIVPR49 was kindly 
provided by Dr. Jordan Tang, Oklahoma Medical Research Foundation.   The amino acid 
sequence of the PR encoded within pET-HIVPR contains Met-36, Ser-37 and Ile-64, instead of 
Ile-36, Asn-37 and Val-64, as found in the HIV-1 89ES061 isolate.45  Mutations M36I, S37N and 
I64V were introduced in pET-HIVPR with the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene), using the mutagenic primers: 5’-GTT CTG GAA GAA ATC AAT CTG CCG GGT 
CGT TGG AAG CCG-3’ and 5’-CGG CTT CCA ACG ACC CGG CAG ATT GAT TTC TTC 
CAG AAC-3’ for M36I and S37N; and 5’-CAG TAT GAT CAG ATC CTG GTT GAA ATC 
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TGC GGT CAC-3’ and 5’-GTG ACC GCA GAT TTC AAC CAG GAT CTG ATC ATA CTG-3’ 
for I64V.  Then, we introduced a TAA termination codon and a HindIII restriction site, using 
primers 5’-CGG TTG CAC TTT GAA CTT CTA AGC TTC CCC GAT TGA AAC TGT TCC 
GG-3’ and 5’-CCG GAA CAG TTT CAA TCG GGG AAG CTT AGA AGT TCA AAG TGC 
AAC CG-3’ to obtain a modified pET-HIVPR construct, designated as pET-HIVPR61.  Plasmids 
for expression of mutant PRs carrying mutations G94S or T96S were obtained with the 
QuikChange mutagenesis kit using pET-HIVPR61 as template and the mutagenic primers: 5’-
CCT GCT GAC TCA GAT CTC TTG CAC TTT GAA CTT CTA AGC-3’ and 5’-GCT TAG 
AAG TTC AAA GTG CAA GAG ATC TGA GTC AGC AGG-3’ for G94S, and 5’-CTG ACT 
CAG ATC GGT TGC TCT TTG AAC TTC TAA GCT TTC-3’ and 5’-GAA AGC TTA GAA 
GTT CAA AGA GCA ACC GAT CTG AGT CAG-3’ for T96S.  In all cases, mutations were 
confirmed by DNA sequencing. 
Expression and purification of mutant and wild-type PRs was carried out essentially as 
described previously.49  Briefly, freshly prepared E. coli BL12(DE3)pLysS containing the plasmid 
pET-HIVPR61, or the mutated PRs were grown in 1 liter of Luria broth medium containing 75 
µg/ml ampicillin and 25 µg/ml chloramphenicol, to an A600 of 0.6-0.8.  After induction with 0.5 
mM isopropyl-β-D-thiogalactopyranoside for 2.5 h, cells were harvested by centrifugation at 
5,000 x g and stored at -20 ºC.  The bacteria (8 g of cell paste) were processed as described to 
obtain a pellet, which contains the majority of the proteins expressed (as inclusion bodies).49  The 
inclusion bodies were solubilized in 1 ml of 10 mM Tris, pH 7.5, 8 M urea and 10 mM 
dithiothreitol, and centrifuged at 100,000 x g.  The clear supernatant was transferred to a 2-ml 
DEAE Sephadex A-25 column (previously equilibrated in the dilution buffer) and permitted to 
flow at room temperature.  Fractions of 0.3 ml were collected and those containing the PR were 
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pooled and stored at 4 ºC. The denatured protein solution in 8 M urea was then acidified by 
mixing with 0.02 volume of 10 % (v/v) trifluoroacetic acid to make a final pH of 3.5, and then 
refolded by dialysis against 1 mM dithiothreitol, 10 mM sodium acetate buffer, pH 3.5.  After 
centrifugation at 100,000 x g, the supernatants were collected, and after addition of glycerol to a 
concentration of 10 % (v/v), samples were stored at -70 ºC.   
 
Oligopeptide substrates and proteolytic assays   
The synthetic nonapeptide substrate Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln, corresponding 
to the MA/CA cleavage site in the natural Gag precursor and the products of cleavage were 
analyzed by reverse-phase high-pressure liquid chromatography (RP-HPLC).50  The PR assays 
were initiated by mixing 5 µl of enzyme, 10 µl of  2x incubation buffer [0.5 M sodium phosphate 
buffer (pH 5.6), containing 4 M NaCl, 10 mM dithiothreitol, 2 mM EDTA and 10 % glycerol] and 
5 µl 0.05 – 10 mM substrate.  The reaction mixture was incubated at 37 ºC for 1 h and terminated 
by the addition of 180 µl of 1 % trifluoroacetic acid.  The hydrolysis products were separated by 
RP-HPLC and analyzed as previously described.51  Kinetic parameters were determined by fitting 
the data obtained at <20 % substrate hydrolysis to the Michaelis-Menten equation by using 
SigmaPlot 8.02 (Systat Software Inc., Richmond, CA) software.  The active enzyme 
concentrations of the wild-type and mutant PRs were determined with the HPLC assay in the 
presence of a substrate concentration of 0.4 mM and 1.25 mM, respectively, and using DMP 323 
as a tight-binding inhibitor of HIV-1 PR.52 DMP 323 was a king gift from Dr. Bruce Korant 
(DuPont Experimental Station).   
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Urea-denaturation assay   
The HPLC assay with concentrations of 50-200 nM (wild-type PR) or 250-900 nM 
(mutant PRs), and 400 µM substrate was used to determine PR activity in the presence of 0-3.2 M 
urea.53  Before adding the substrate, the enzyme was incubated in the presence of urea (at 
appropriate concentrations) for 5 min at 37 ºC.  The UC50 values for half-maximal velocity were 
obtained by plotting the initial velocities against concentration of urea and fitting to a curve for 
solvent-denaturation of protein using SigmaPlot 8.02 software.  
 
Kd determination   
Specific activity was measured as a function of dimeric enzyme concentration in 0.25 M 
sodium phosphate buffer (pH 5.6), containing 2 M NaCl, 5 mM dithiothreitol, 1 mM EDTA and 5 
% glycerol, using a 1.25 mM substrate concentration.  Samples were incubated for 1 h at 37 ºC, 
and processed for HPLC analysis as described above.53,54  
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LEGENDS TO FIGURES 
Figure 1.  Replication kinetics of wild-type HIV-1 and mutants F130W and T58S/F130W in MT-
4 cells. MT-4 cells (6 x 106) were infected at a multiplicity of infection of 0.0001 TCID50 per cell. 
Infections were monitored by measuring RT activity (a) and p24 production (b). Cell lysates 
collected when the p24 levels reached the highest values (day 4 for wild-type HIV-1, day 6 for 
mutant T58S/F130W, and day 9 for mutant F130W) were analyzed by Western blot (c – f).  
Immunoblots were probed with monoclonal antibodies against p24 (c), IN (d), the RNase H 
domain of the RT (e), and the RT heterodimer (f).  Samples were normalized using a β-actin-
specific antibody. 
Figure 2. Emergence of compensatory mutations in the PR-coding region of HIV-189ES061 
containing a F130W mutation in its RT-coding region.  (a) Sequence heterogeneities in viral 
stocks derived from transfections of COS-1 cell monolayers, obtained with mutant HIV-1 
carrying the amino acid change F130W in the RT-coding region.  Numbers indicate the estimated 
relative percentage of wild-type and mutant virus, as determined after DNA sequencing of the 
whole viral population. (b) Clonal analysis of HIV variants found in stock 1, before and after two 
serial passages in MT-4 cells, at a multiplicity of infection of 0.001 TCID50 per cell. The ratios 
shown on the right indicate the number of clones containing the mutations studied, relative to the 
total number of clones analyzed. (c) Kinetics of imposition of Ser over Gly-94 in an infection of 
MT-4 cells (106), using the virus obtained from stock 2, at a multiplicity of infection of 0.0001 
TCID50 per cell.  RT-PCR was carried out with culture supernatants collected at various days after 
infection, using primers 198U5U (5´-GTC TGT TGT GTG ACT CTG GT-3´) and 292GD (5´-
GAT TGA CTG CGA ATC GTT C-3´).  Numbers in the lower panel indicate the relative 
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percentage of virus carrying a mutated (G94S) or a wild-type PR, while maintaining the RT 
mutation F130W, as determined by DNA sequencing.  
Figure 3. Compensatory effects of the PR mutation G94S on the replication capacity of HIV-1 
clones carrying the F130W substitution in their RT. (a) Characterization of virus recovered from 
culture supernatants of 293T cell monolayers transfected with HIV-1 cDNA clones carrying the 
indicated mutations. The p24 antigen levels were determined by ELISA.  Culture supernatants 
were titrated in MT-2 cells. Infectivity values (expressed as TCID50 units per pg of p24) are 
averages of two independent determinations.  (b) Replication kinetics of wild-type and mutant 
HIV-1 clones in MT-4 cells. MT-4 cells (106) were infected with a volume of culture supernatants 
of 293T cell monolayers transfected with the corresponding proviral DNA, containing 1 ng of p24 
antigen.  Samples were withdrawn from the infected cultures at the indicated times and virion-
associated RT activity was determined as described.22 
Figure 4.  Analysis of p51 mutants containing F130W.  M7 proviral DNA was transfected into 
293T cells alone or together with wild-type or mutant vpr-p51/p66 and vpr-IN expression plasmid 
DNAs.  (a) Virion incorporation and proteolytic processing of trans-heterodimeric RT. 
Immunoblot analysis of transfection-derived virions obtained with M7 plus vpr-p51/p66, 
vpr∆p51/p66, vpr-p51(F130W)/p66, and vpr-p51(T58S/F130W)/p66, using the RT-specific 
monoclonal antibody 8C4 (upper panel) and a CA-specific monoclonal antibody 183-H12-5C 
(lower panel). (b)  Immunoblot analysis of the expression of p66 and α-tubulin in the transfected 
293T cells. Samples were analyzed with a mixture of monoclonal antibodies against the RNase H 
domain of HIV-1 RT (7E5) and α-tubulin.   
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Figure 5.  Immunoblot analysis of mutant heterodimers in PM-3 virions (containing catalytically 
inactive viral PR).  Virus obtained by cotransfection of PM-3 together with vpr-p51/p66 
expression plasmids were analyzed by immunoblot using a monoclonal antibody against the RT.  
Figure 6.  PR stability.  (a) Sensitivity to urea: wild-type HIV-1 PR (filled circles) (UC50 = 1.22 
M), G94S (open circles) (UC50 = 0.63 M), and T96S (filled triangles) (UC50 = 0.74 M).  (b) Dimer 
dissociation: wild-type HIV-1 PR (filled circles) (Kd < 0.37 nM, no dissociation observed), G94S 
(open circles) (Kd = 26.3 ± 11.7 nM), and T96S (filled triangles) (Kd = 4.94 ± 1.07 nM). 
Figure 7.  Location of Gly-94 and Thr-96 in the HIV-1 PR homodimer.  (a) Crystallographic 
structure of HIV-1 PR complexed with an inhibitor (Protein Data Bank File 7HVP) showing the 
location of the relevant residues.  The dimerization interface of the enzyme is shown below.  PR 
subunits are represented with solid ribbon diagrams (red and green for subunits A and B, 
respectively).  CPK models are used to represent a substrate analogue bound to the PR (white), 
and the side chains of Gly-94 and Thr-96 (blue and magenta, respectively). (b) Spatial 
arrangement and hydrogen bonding interactions observed in the four-stranded antiparallel β-sheet 
that stabilizes the dimeric structure of the viral PR.   As above, Gly-94 and Thr-96 are shown in 
blue and magenta, respectively. 
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FOOTNOTES 
Present address: Alok Mulky, HIV Drug Resistance Program, National Cancer Institute, 
Frederick, Maryland, USA. 
Abbreviations used:  HIV-1, human immunodeficiency virus type-1; MA, matrix protein; CA, 
capsid protein; NC, nucleocapsid protein; PR, protease; RT, reverse transcriptase; IN, integrase; 
DMEM, Dulbecco’s modified Eagle’s medium; TCID50, tissue culture infectious dose 50; RP-
HPLC, reverse-phase high-pressure liquid chromatography. 
* E-mail address of the corresponding author: lmenendez@cbm.uam.es 
 
 
 
 
Table 1.  Abbreviations for plasmids 
 
Plasmid Abbreviation 
pSG3M7 M7 
pLR2P-vpr-45Prop51-IRES-p66 vpr-p51/p66 
pLR2P-vpr∆p51-IRES-p66 vpr∆p51/p66 
pLR2P-vpr-p51(F130W)-IRES-p66 vpr-p51(F130W)/p66 
pLR2P-vpr-p51(T58S/F130W)-IRES-p66 vpr-p51(T58S/F130W)/p66 
pLR2P-vpr-IN vpr-IN 
 
 
Table 1
  
Table 2 .  Kinetic parameters for the cleavage of peptide VSQNYPIVQ by wild-type 
and mutant HIV-1 PRs. 
Enzyme kcat (s-1) a Km (mM) kcat/Km (mM s-1) 
WT 6.14 ± 0.32 0.20 ± 0.03 30.70 ± 4.88 
G94S 1.40 ± 0.08 1.01 ± 0.12 1.39 ± 0.18 
T96S 4.57 ± 0.61 1.14 ± 0.13 4.01 ± 0.70 
 
a Catalytic constants were referred to the amount of active PR used in the assays (7.5 
nM for WT PR, 63.5 nM for mutant G94S, and 23.5 nM for mutant T96S).  PR active 
site titrations were carried out with DMP 323.  Inhibition constants (Ki) obtained for this 
compound were 0.5 nM (for wild-type PR), 8.5 nM (for G94S), and 4.3 nM (for T96S). 
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